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Summary
Background Real-world biologic drug survival is an important proxy measure for
effectiveness. Predictors of drug survival may help patients with psoriasis choose
between biologic therapies.
Objectives (i) To assess the relative drug survival of adalimumab, ustekinumab and
secukinumab in patients with psoriasis. (ii) To investigate predictors of biologic
drug survival.
Methods A prospective cohort study was performed in the British Association of
Dermatologists Biologics and Immunomodulators Register (BADBIR) between
November 2007 and August 2019. We performed survival analysis and fitted a
flexible parametric survival model for biologic discontinuation due to ineffective-
ness.
Results In total 9652 patients were included: 5543 starting on adalimumab
(574%), 991 on secukinumab (103%) and 3118 on ustekinumab (323%). The
overall drug survivals of adalimumab, secukinumab and ustekinumab in year 1
were 078 [95% confidence interval (CI) 077–079], 088 (95% CI 086–091)
and 088 (95% CI 087–089), respectively. The adjusted hazard ratios (adjHRs)
for discontinuation of adalimumab and secukinumab compared with ustek-
inumab were 211 (95% CI 176–254) and 067 (95% CI 040–111), respec-
tively. The presence of psoriatic arthritis predicted for survival in the
adalimumab and secukinumab cohorts (adjHR 067, 95% CI 051–088 and
070, 95% CI 040–124, respectively), but for discontinuation in the ustek-
inumab cohort (adjHR 142, 95% CI 112–181). Previous exposure to biologic
therapies predicted for discontinuation in the ustekinumab and secukinumab
cohorts (adjHR 154, 95% CI 126–189 and 149, 95% CI 091–245, respec-
tively) and for survival in the adalimumab cohort (adjHR 071, 95% CI 055–
092).
Conclusions Secukinumab and ustekinumab have similar sustained drug survival,
while adalimumab has a lower drug survival in patients with psoriasis. Psoriatic
arthritis and previous biologic experience were predictors with differential effects
between the biologic therapies.
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What is already known about this topic?
• There is conflicting evidence over the real-world drug survival of secukinumab in
patients with psoriasis.
• Data from registries to date suggest that secukinumab has a lower drug survival
than that reported from clinical trials.
What does this study add?
• This study found that secukinumab and ustekinumab had similar sustained drug
survival in the real world, while the drug survival of adalimumab was lower, sug-
gesting that the real-world drug survival of secukinumab is higher than previously
reported.
• We found that psoriatic arthritis and previous biologic experience had differential
effects on drug discontinuation in the three biologic cohorts. These predictors may
help patients and clinicians choose the most appropriate biologic therapy.
Biologic therapies are the current standard of care for patients
with moderate-to-severe psoriasis. Patients treated with biologic
therapies in the real world often have to discontinue treatment
and/or switch biologic agents over time due to loss of effective-
ness or the development of adverse events. Our group has shown
that there is only a 53%1 to 58%2 probability that patients with
psoriasis will remain on a biologic therapy for at least 3 years.
Treatment failure leads to disease flares and reduced quality of
life, as well as higher costs to the healthcare system.3
Drug survival, or persistence, is a proxy measure for the
effectiveness, safety and tolerability of a medicine. This is
defined by the duration of time from initiation to discontinua-
tion of therapy. A recent systematic review and meta-analysis
identified different predictors of biologic drug survival in pso-
riasis across 16 cohort studies, including female sex and obe-
sity, which predicted for discontinuation, and psoriatic
arthritis (PsA), which predicted for persistence.4 Identifying
predictors of differential biologic survival may have the poten-
tial to help patients and clinicians identify the right biologic
first time, and therefore avoid or delay treatment failure.
Our objectives were firstly, to report on the drug survival of
the three most commonly used biologic therapies for psoriasis
in the UK and the Republic of Ireland – adalimumab, secuk-
inumab and ustekinumab; and secondly, to identify clinical pre-
dictors that affect their drug survival. To achieve our objectives
we used data from the British Association of Dermatologists Bio-
logics and Immunomodulators Register (BADBIR), a large, rep-
resentative, national, prospective psoriasis registry, to perform
descriptive and survival analyses for the three biologic therapies,
and to develop an adjusted flexible parametric model.
Patients and methods
Data source and study population
The structure and study design of BADBIR and the baseline
characteristics of the patients recruited have been reported
previously.5,6 Briefly, BADBIR is a large, ongoing pharma-
covigilance registry of patients with psoriasis in the UK and
the Republic of Ireland that was established in September
2007. To date, 164 secondary-care dermatology centres have
contributed data to BADBIR. The National Institute for Health
and Care Excellence recommends that all patients with psoria-
sis on biologic therapies in England should be registered on
BADBIR. Patients are recruited to three different cohorts
depending on the drug of initiation: nonbiologic systemic
therapies, oral small molecules and biologic therapies. Data are
collected 6 monthly for the first 3 years, then annually there-
after. Detailed information is collected at baseline and follow-
up. Importantly, details of the biologic therapies, including
start and stop dates, reasons for discontinuation and gaps in
treatment, are obtained during follow-up visits. Data from the
start of the registry until August 2019 were used in this study.
Data analysis
Patients eligible for this study had chronic plaque psoriasis,
and were recruited or switched to the biologic cohort starting
either adalimumab (Humira), secukinumab (Cosentyx) or
ustekinumab (Stelara). Patients contributed data to the study if
they had one or more follow-up visits. We excluded patients
on biologic therapies other than the three drugs listed above.
We also excluded patients who did not initiate the three bio-
logic therapies at registration to ensure better capture of base-
line predictors. We used the same definition for drug survival
as in our previous studies,1 with discontinuation of therapy
defined as any gap in treatment for more than 90 days. We
censored patients at the last available follow-up date. Reasons
for discontinuation were classified as ineffectiveness, adverse
events or others.
We performed a descriptive summary of the baseline char-
acteristics of the three biologic cohorts, and report the num-
ber of missing values in each cohort. We also performed a
descriptive summary of all adverse events leading to biologic
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discontinuation, which were reported and coded using the
Medical Dictionary for Regulatory Activities (MedDRA) classi-
fication. Data points with fewer than five participants were
censored due to data confidentiality. Biologic drug survival
was examined using Kaplan–Meier survival analysis, and sur-
vival functions at 1 and 2 years were reported. Biologic drug
survival was stratified by the reasons for discontinuation.
Model development
The model for the outcome of biologic discontinuation due to
ineffectiveness was utilized as a proxy for biologic treatment
failure. We identified a priori potential predictors for drug sur-
vival or discontinuation from our previous studies, clinical
observations and a systematic review.4 We used a two-tier pre-
dictor selection process. The first tier identified covariates that
were consistently found to be associated with biologic drug
survival in psoriasis across different studies. These covariates
were age, sex, body mass index and PsA. We included other
covariates in the second tier, which included predictors in some
but not previous studies of drug survival, as well as other
covariates that were not previously evaluated. These covariates
were the previous biologic exposure status, Psoriasis Area and
Severity Index, smoking intake, alcohol intake, chronic obstruc-
tive pulmonary disease, type 1 diabetes, number of comorbid
conditions, needing to use methotrexate or ciclosporin con-
comitantly during biologic therapy, waist circumference, nail
psoriasis, palmoplantar psoriasis, flexural psoriasis, scalp psoria-
sis and unstable psoriasis. We investigated obesity (≥ 30 kg
m2), previous biologic exposure status, diabetes, palmoplantar
psoriasis, flexural psoriasis, diabetes, sex and PsA, which were
the selected dichotomous predictors, for effect modification
with biologic therapy on drug discontinuation.
A flexible parametric survival model was fitted using the
stpm2 command in Stata (StataCorp, College Station, TX,
USA) to adjust for and identify predictors of discontinuation.
In contrast to Cox regression models, which are semiparamet-
ric and do not estimate the baseline hazard function (equiva-
lent to the hazard function when all covariates are set to
zero), this method uses a parametric modelling approach, and
restricted cubic splines are fitted to model the baseline hazard.
This approach allows for estimation of the absolute measures
of risk in time-to-event data, as well as the modelling of non-
proportional effects of covariates.7 The number of knots for
the restricted cubic spline function was selected to give the
smallest Akaike information criterion and the Bayesian infor-
mation criterion, which are criteria for model selection based
on the likelihood function.
We tested for nonproportionality of the comparative bio-
logic survival by comparing two models, one of which allows
for time-dependent effects of the biologic therapies, with the
likelihood ratio test. Missing data were accounted for with 20
multiply imputed datasets. We used the mfpmi command in
Stata8 to test the second-tier covariates for inclusion in the
model using backward stepwise regression (P-value of 01 as
the cutoff), along with testing for fractional polynomial
transformation for continuous predictors to account for non-
linearity, while all first-tier covariates were forced into the
model. Model fit, calibration and discrimination were also
evaluated. The model’s fit, which measures how much of the
variation in the outcome is explained by the model, was
assessed by the Royston and Sauerbrei R2D. Model calibration,
which measures the agreement between the observed out-
comes and the predicted outcomes, was assessed by the cali-
bration slope. Model discrimination, which measures how
well the model separates individuals who discontinue the bio-
logic therapy from those who do not, was assessed by the
Harrell C-statistic.
Sensitivity analysis
A sensitivity analysis restricting the time period to when all
three biologic therapies were available in BADBIR was per-
formed. All analyses were performed using Stata 151. The
study was reported according to the STROBE guidelines.
Ethical approval
BADBIR was approved in March 2007 by NHS Research Ethics
Committee North West England, reference 07/MRE08/9. All
individuals gave written informed consent for their participa-
tion in the registry.
Results
In total 9652 patients were eligible for inclusion, with 5543
(574%) starting on adalimumab, 991 (103%) on secuk-
inumab and 3118 (323%) on ustekinumab. The overall med-
ian age of the cohort was 450 years [interquartile range
(IQR) 350–540], with a median body mass index of 300
kg m2 (IQR 261–349) and a median Psoriasis Area and
Severity Index of 154 (IQR 107–189). The baseline charac-
teristics of the cohort separated by biologic therapy, along
with the proportions of missing data, are presented in
Table 1. Notable differences between the three biologic
cohorts included the proportion of patients with PsA (adali-
mumab 227%, secukinumab 228%, ustekinumab 155%),
the proportion of biologic-naive patients (adalimumab 863%,
secukinumab 729%, ustekinumab 748%) and the proportion
of patients on concomitant methotrexate during follow-up
(adalimumab 151%, secukinumab 72%, ustekinumab 94%).
Adalimumab had the longest accrued follow-up time, with
a median of 20 years (IQR 08–42), followed by ustek-
inumab with a median of 19 years (IQR 08–36). Secuk-
inumab had the shortest follow-up time, with a median of
10 years (IQR 05–18). The survival functions for the three
biologic cohorts are listed in Table 2. Broadly, secukinumab
and ustekinumab had similar sustained survival functions after
1 and 2 years across the different reasons for discontinuation.
Comparatively, adalimumab had the lowest survival function
at all timepoints and across all reasons for discontinuation (i.e.
for both ineffectiveness and adverse events) (Table 2). A
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Kaplan–Meier plot summarizing drug survival due to either
ineffectiveness or adverse events for all three biologic therapies
is presented in Figure 1.
The adverse events that led to biologic discontinuation are
presented Table S1 (see Supporting Information), coded by
the MedDRA system organ classification. The three most com-
mon codes for adverse events were infections and infestations,
surgical and medical procedures, and general disorders and
administration-site conditions. Fewer than five event codes of
noninfective colitis were present in the secukinumab and
ustekinumab cohorts, while there were eight in the adali-
mumab cohort. There were fewer than five events coded as
fungal infections in the secukinumab cohort, with none in
either the adalimumab or ustekinumab cohorts. The reasons
for discontinuation other than ineffectiveness or adverse events
are summarized in Table S2 (see Supporting Information).
Table 1 Baseline demographic and disease characteristics of the three biologic cohorts
Baseline characteristic Adalimumab (n = 5543) Secukinumab (n = 991) Ustekinumab (n = 3118)
Age (years) 450 (350–530) 470 (360–550) 450 (350–550)
Female sex 2288 (413) 385 (388) 1257 (403)
Body mass index (kg m2) 297 (261–343) 304 (266–351) 303 (261–358)
Missing 336 (61) 52 (52) 195 (63)
Waist circumference (cm) 1000 (900–1110) 1020 (920–1140) 1020 (910–1140)
Missing 579 (105) 139 (142) 388 (125)
Alcohol units per week 30 (00–120) 30 (00–100) 30 (00–100)
Alcohol intake by category
No documented alcohol intake 1704 (307) 366 (369) 1085 (348)
Lower-risk drinkinga 2717 (490) 484 (488) 1523 (488)
Hazardous drinkingb 576 (104) 101 (102) 302 (97)
Harmful drinkingc 85 (15) 10 (10) 54 (17)
Missing 461 (83) 30 (30) 154 (49)
Smoking status
Never smoked 1836 (331) 361 (364) 1076 (345)
Previous smoker 1838 (332) 360 (363) 1114 (357)
Current smoker 1436 (259) 251 (253) 802 (257)
Missing 433 (78) 19 (19) 126 (40)
Number of cigarettes smoked per day 00 (00–40) 00 (00–20) 00 (00–30)
Disease duration (years) 200 (120–290) 190 (100–300) 200 (110–300)
Baseline DLQI 180 (120–240) 180 (120–230) 180 (120–230)
Missing 2479 (447) 370 (373) 1398 (448)
Baseline PASI 140 (108–191) 136 (106–189) 136 (105–186)
Missing 683 (123) 111 (112) 330 (106)
Psoriatic arthritis 1257 (227) 226 (228) 483 (155)
Nail psoriasis 3090 (557) 504 (509) 1604 (514)
Palmar psoriasis 1034 (187) 183 (185) 578 (185)
Scalp psoriasis 3902 (704) 693 (699) 2237 (717)
Flexural psoriasis 2076 (375) 331 (334) 1131 (363)
Unstable psoriasis 607 (110) 101 (102) 317 (102)
Number of previous biologic therapies
0 4781 (863) 722 (729) 2333 (748)
1 606 (109) 162 (163) 476 (153)
2 125 (23) 72 (73) 217 (70)
≥ 3 31 (06) 35 (35) 92 (30)
Any treatment with methotrexate during follow-up 839 (151) 71 (72) 294 (94)
Any treatment with ciclosporin during follow-up 315 (57) 16 (16) 142 (46)
Number of comorbid conditions
0 1510 (272) 311 (314) 867 (278)
1–2 2953 (533) 499 (504) 1552 (498)
3–4 898 (162) 144 (145) 544 (174)
≥ 5 182 (33) 37 (37) 155 (50)
COPD 94 (17) 24 (24) 79 (25)
Diabetes 468 (84) 119 (120) 352 (113)
Dyslipidaemia 530 (96) 74 (75) 296 (95)
Hypertension 1304 (235) 232 (234) 797 (256)
The data are presented as the median (interquartile range) or n (%). COPD, chronic obstructive pulmonary disease; DLQI, Dermatology Life Qual-
ity Index; PASI, Psoriasis Area and Severity Index. aLower risk: < 21 units per week in men, < 14 units per week in women. bHazardous: 21–49
units per week in men, 14–34 units per week in women. cHarmful: ≥ 50 units per week in men, ≥ 35 units per week in women.
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We stratified crude drug survival in the three biologic
cohorts by PsA (Table S3; see Supporting Information) and by
previous biologic exposure (Table S4; see Supporting Informa-
tion). There was higher drug survival in the adalimumab PsA
cohort, while for ustekinumab drug survival was higher in the
cohort without PsA. Both secukinumab and ustekinumab had
lower drug survival in the biologic-experienced cohort com-
pared with the biologic-naive cohort, while for adalimumab
there was little difference. The sensitivity analysis restricting
the cohort to those participants starting biologics after 1
September 2013 found similar drug survival to the main anal-
ysis (Table S5; see Supporting Information).
Model development and performance
Univariable analysis for each covariate is presented in Table S6
(see Supporting Information). Effect modification between
choice of biologic and both PsA and biologic exposure status
was statistically significant, and interaction terms for these
covariates were included in the multivariable analysis.
Backwards elimination left the covariates of concomitant
methotrexate, concomitant ciclosporin, number of comorbidi-
ties, waist circumference, palmoplantar psoriasis, flexural pso-
riasis and diabetes in the multivariable flexible parametric
model (Table 3). The adjusted hazard ratios for discontinua-
tion of adalimumab and secukinumab compared with ustek-
inumab were 211 [95% confidence interval (CI) 176–254]
and 067 (95% CI 040–111), respectively. The overall
adjusted survival curve standardized for the covariate pattern is
presented in Figure S1 (see Supporting Information), and the
adjusted survival curves by biologic therapy standardized for
the covariate pattern are presented in Figure S2 (see Support-
ing Information). These adjusted survival curves show similar
differential drug survival for the three biologic therapies com-
pared with the Kaplan–Meier plots in Figure 1, but CIs are
added for precision around the estimate of drug survival.
Regarding the overall model performance, the Royston and
Sauerbrei R2D was 012 (95% CI 010–015). The Harrell’s C-
index for model discrimination was 062 (95% CI 061–
063). The calibration slope measuring model calibration was
100 (95% CI 089–111).
Discussion
In our analysis of a large real-world cohort of patients with
severe psoriasis, we showed that secukinumab and ustek-
inumab had similar sustained drug survival over 2 years, and
adalimumab had lower drug survival over this period of time.
We found that PsA and previous biologic experience were
predictors that had a differential effect on the risk of discon-
tinuation due to ineffectiveness in the three biologic cohorts.
The strengths of this study include the use of one of the
largest prospective registries for patients with psoriasis in the
world to investigate biologic drug survival. It also represents
the largest prospective observational real-world cohort study
Table 2 Survival functions at years 1 and 2 for the three biologic cohorts stratified by reason for drug discontinuation
Reasons for
discontinuation
Adalimumab (n = 5543) Secukinumab (n = 991) Ustekinumab (n = 3118)
Total participants/
discontinuations
Survival
function (95% CI)
Total participants/
discontinuations
Survival
function (95% CI)
Total participants/
discontinuations
Survival
function (95% CI)
All reasons
Year 1 3818/1155 078 (077–079) 510/82 088 (086–091) 2169/330 088 (087–089)
Year 2 2793/556 066 (064–067) 199/53 077 (073–080) 1484/233 077 (076–079)
Ineffectiveness
Year 1 3818/628 087 (086–088) 510/44 093 (091–095) 2169/156 094 (093–095)
Year 2 2793/301 080 (078–081) 199/28 087 (084–090) 1484/107 089 (087–090)
Adverse events
Year 1 3818/323 093 (093–094) 510/28 096 (095–097) 2169/103 096 (095–097)
Year 2 2793/143 089 (088–090) 199/12 093 (091–095) 1484/60 093 (092–094)
Others
Year 1 3818/204 096 (095–096) 510/10 098 (097–099) 2169/71 097 (097–098)
Year 2 2793/112 092 (092–093) 199/13 094 (091–096) 1484/66 094 (093–095)
CI, confidence interval.
Figure 1. Crude drug survival for discontinuation due to either
ineffectiveness or adverse events in the British Association of
Dermatologists Biologics and Immunomodulators Register (BADBIR).
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assessing secukinumab in patients with psoriasis to date.
Detailed data capture allowed us to differentiate by drug dis-
continuation reason, which is vital for clinical interpretation
of drug survival,9 as well as allowing for the inclusion of
many covariates that are clinically relevant for drug discontin-
uation.
However, the overall predictive performance of the model
was limited. Similarly to our previous work to develop a
model using clinical baseline factors to predict serious infec-
tion in patients starting biologic therapies,10 clinical factors
appear to be poorly predictive of drug discontinuation due to
ineffectiveness. Work by the Psoriasis Stratification to Optimise
Relevant Therapy (PSORT) consortium in the UK has identi-
fied that pharmacokinetic factors such as early drug levels are
important for prediction of later treatment response for adali-
mumab11 and ustekinumab,12 and it may be that the
determinants of biologic pharmacokinetics such as propensity
to develop antidrug antibodies or other factors affecting distri-
bution and bioavailability of biologic therapies are more pre-
dictive of drug ineffectiveness than are clinical covariates. In
addition, there may be other unmeasured factors that might
be predictive of biologic ineffectiveness, such as genomic and
transcriptomic data, and drug adherence. Despite the fact that
the secukinumab cohort was smaller and had a shorter follow-
up than the adalimumab and ustekinumab cohorts, we report
the largest real-world secukinumab cohort to date. Similarly to
our previous studies, the Dermatology Life Quality Index13
could not be included as a covariate due to high levels of
missing data.
We found that the effects of having PsA and having previ-
ously been treated with biologic therapies varied between the
different biologic cohorts. Participants with PsA had a 42%
increase in the risk of discontinuing ustekinumab, while there
was a similar protective effect against discontinuation for
secukinumab and adalimumab. Given that ustekinumab has a
lower efficacy for PsA than adalimumab or secukinumab, this
result suggests that patients persisted on adalimumab due to
additional beneficial effects on PsA. Studies investigating the
drug survival and effectiveness of these biologics on a larger
cohort of patients with PsA in order to replicate these findings
are required. It is important to note that adalimumab had a
lower drug survival in patients both with and without PsA
compared with the two other biologic therapies (Table S3; see
Supporting Information).
Similarly, prior exposure to biologic therapies had a protec-
tive effect on drug survival in participants on adalimumab,
compared with a negative effect on drug survival in partici-
pants on ustekinumab or secukinumab (Table 3). This statisti-
cal interaction may be a function of the higher proportion of
patients having received three or more biologic therapies in
the ustekinumab and secukinumab cohorts compared with the
adalimumab cohort (Table 1), and warrants further stratified
analysis in each separate line of biologic therapy as more data
accrue over time. Further data accrual would also allow for
investigation of whether failure due to blockade of a specific
pathway might be predictive of loss of effectiveness in these
three biologic therapies.
In addition to female sex, concomitant methotrexate and
concomitant ciclosporin, which are previously identified pre-
dictors for drug discontinuation,1 diabetes, flexural psoriasis
and palmoplantar psoriasis were included as predictors for
drug discontinuation (Table 3). Diabetes could reflect an
inflammatory burden14 that is additional to the burden from
psoriasis. Flexural and palmoplantar areas of involvement with
psoriasis are hard to treat, can be highly symptomatic, and are
associated with a higher psychosocial burden given that these
areas are either highly visible or have a high impact on quality
of life.15–17 However, these predictors did not have differen-
tial effects in the three biologic cohorts.
The Danish DERMBIO registry has reported previously on
the drug survival of secukinumab.18 In the first analysis, pub-
lished in 2018, the authors found a low drug survival for
Table 3 Final multivariable prognostic model for drug survival
(discontinuation due to ineffectiveness)
Covariate Hazard ratio (95% CI)
Age 100 (099–100)
Female sex 128 (116–142) *
Baseline Psoriasis Area and Severity Index 101 (101–102) *
Body mass index (kg m2) a 003 (001–012) *
Number of comorbid conditionsb, c 100 (100–100)
Waist circumference (cm) 100 (100–101)
Palmoplantar psoriasis 112 (099–127)
Flexural psoriasis 112 (101–124) *
Diabetes 134 (115–157) *
Concomitant methotrexate 121 (103–142) *
Concomitant ciclosporin 253 (198–322) *
Biologic therapies
Ustekinumab Reference
Adalimumab 211 (176–254) *
Secukinumab 067 (040–111)
Psoriatic arthritis (ustekinumab) 142 (112–181) *
Psoriatic arthritis (adalimumab) 067 (051–088) *
Psoriatic arthritis (secukinumab) 070 (040–124)
Biologic experienced (ustekinumab) 154 (126–189) *
Biologic experienced (adalimumab) 071 (055–092) *
Biologic experienced (secukinumab) 149 (091–245)
CI, confidence interval. Comparisons of the model fit statistics
suggested three knots and one knot to be placed for the
restricted cubic splines to model the baseline hazard and the
time-dependent effect of biologic treatment, respectively. *Statis-
tically significant results (P < 005). aBody mass index transfor-
mation = (body mass index / 10)2. bThe number of comorbid
conditions is the total number from the following conditions:
hypertension, angina, myocardial infarction, stroke, epilepsy,
asthma, chronic obstructive pulmonary disease, peptic ulcer,
renal disease, liver disease, tuberculosis, demyelination, diabetes,
impaired glucose tolerance, depression, dyslipidaemia, cancer
(excluding skin cancer), immunodeficiency syndromes, thyroid
disease and other diseases (any other disease counted as 1).
cNumber of comorbid conditions transformation = [(no. comor-
bid conditions + 1) / 10]2.
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secukinumab in 196 treatment series. Treatment series include
patients in the analysis multiple times for different drug expo-
sures. Survival functions at specific timepoints were not
reported, with the secukinumab follow-up being too short to
approximate the 1-year survival function. However, secuk-
inumab was found to have a higher probability of discontinu-
ation due to any cause than ustekinumab (hazard ratio 243,
95% CI 182–325). Only 215% of these treatment series
were in biologic-naive patients. The same group subsequently
published a more recent analysis of their cohort, with 368
patients on secukinumab (407% biologic-naive) included in
the analysis.19 The survival functions for secukinumab were
not reported in numerical format but approximated to around
850% for the biologic-naive cohort and 670% for the bio-
logic-experienced cohort at 1 year.
The Dutch BioCAPTURE registry has also reported on the
drug survival of secukinumab.20 The authors found a 1-year
drug survival of 760% in 196 patients on secukinumab, and,
similarly to the DERMBIO registry, only 168% of patients on
secukinumab were biologic naive, with a median number of
biologics before secukinumab of two. In the stratified analysis,
biologic-naive patients (n = 33) had a 1-year survival function
of 900%, while biologic-experienced patients (n = 163) had
a 1-year survival function of 740%.
The above studies are limited due to small sample sizes and
a skew towards selected biologic-experienced patients. Com-
pared with these two registries, in BADBIR patients are treated
earlier with secukinumab in their treatment pathway, with a
much higher proportion of biologic-naive patients (729%)
and a significantly larger (n = 991) secukinumab cohort. This
explains the more definitive finding of a higher overall drug
survival of secukinumab in BADBIR compared with these two
registries, although the stratified drug survival between bio-
logic-naive and biologic-experienced patients on secukinumab
between BADBIR and BioCAPTURE and DERMBIO are similar.
Contrary to the studies referred to above, the overall persis-
tence in users of secukinumab is similar to that with ustek-
inumab, which was previously shown to have the highest
drug survival compared with adalimumab, infliximab and
etanercept in patients with psoriasis. The results in the current
study therefore give real-world evidence to support the posi-
tion of secukinumab as a first-line biologic therapy along with
ustekinumab and adalimumab in the British Association of
Dermatologists guidelines for biologic therapy for psoriasis
published in 2017.21
In contrast to the results from the CLEAR randomized con-
trolled trial,22 which found that secukinumab had higher
efficacy for the treatment of psoriasis than ustekinumab,
secukinumab did not have a corresponding superior drug sur-
vival when compared with ustekinumab in this study. The
more frequent monthly dosing regimen of secukinumab com-
pared with the 3-monthly regimen of ustekinumab may
explain this discrepancy, as drug survival is a proxy measure
not only for drug effectiveness but also for ease of use.
We have identified PsA and previous biologic experience as
factors that differentiate between the three biologic therapies.
Figure 2(a) shows an example of a typical patient with psoria-
sis, in whom PsA is a factor that differentiates between the
three different biologic therapies, and with the expected drug
survival over time adjusted for all other factors. Figure 2(b)
shows a similar figure but with the differentiating factor being
prior experience of a biologic therapy. Individualized drug
survival predictions such as these may help patients and clini-
cians choose between the three biologic therapies based on
these two clinical baseline characteristics.
In conclusion, secukinumab and ustekinumab have similar
sustained drug survival that is higher than adalimumab in
BADBIR. We identified PsA and previous biologic exposure as
factors that have a differential effect on drug survival depen-
dent on the choice of biologic therapy. This information will
help patients make an informed decision to start a biologic
therapy based on drug survival outcome.
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Figure 2. Predicted survival curves from the flexible parametric model
for a typical male patient with psoriasis (age 45 years, body mass index
30 kg m2, waist 101 cm, Psoriasis Area and Severity Index 20, two other
comorbid conditions, no flexural or palmoplantar disease, no diabetes,
not on concomitant therapies). Survival curves for all three biologic
therapies in (a) typical biologic-naive patients with or without psoriatic
arthritis (PsA) and (b) typical patients without PsA in either the biologic-
naive or biologic-experienced subgroups. The predicted survival curves
stratified by treatment with corresponding 95% confidence intervals are
presented in Supplementary Figures 3a–c and 4a–c.
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Fig S1. Adjusted survival curve standardizing over the
covariate pattern of the overall cohort, with the grey shaded
area denoting the 95% confidence interval.
Fig S2. Adjusted survival curves standardizing over the
covariate patterns for the adalimumab, secukinumab and
ustekinumab cohorts, with the dotted lines denoting the 95%
confidence intervals.
Fig S3. Predicted survival curves for the patient from Figure
2a-b, a typical male patient with psoriasis (age 45, body mass
index 30, waist 101 cm, PASI 20, 2 other comorbid condi-
tions, no flexural/palmoplantar disease, no diabetes, not on
concomitant therapies) for all three biologic therapies (biolo-
gic-naı¨ve) with or without PsA, stratified by the three thera-
pies with corresponding 95% confidence intervals (dotted
lines).
Fig S4. Predicted survival curves for the patient from Fig-
ure 2a–b, a typical male patient with psoriasis (age 45, body
mass index 30, waist 101 cm, PASI 20, 2 other comorbid
conditions, no flexural/palmoplantar disease, no diabetes, not
on concomitant therapies) for all three biologic therapies
(without PsA) in both biologic-naı¨ve and biologic-experienced
subgroups, stratified by the three therapies with corresponding
95% confidence intervals (dotted lines).
Table S1. Adverse events leading to biologic discontinua-
tion, stratified by biologic cohort.
Table S2. All reasons for discontinuation other than ineffec-
tiveness or adverse events.
Table S3. Survival functions of the three biologic cohorts at
years 1 and 2 for discontinuation due to ineffectiveness, strati-
fied by psoriatic arthritis status.
Table S4. Survival functions for discontinuation due to
ineffectiveness or adverse events for the three biologic cohorts
at years 1 and 2, stratified by previous biologic experience.
Table S5. Survival function for discontinuation due to inef-
fectiveness or adverse events for the three biologic cohorts at
years 1 and 2, restricted to all participants starting the drug
after 1 September 2013.
Table S6. Univariable (complete-case) analysis of potential
predictors of drug survival from flexible parametric survival
models with discontinuation due to ineffectiveness as the out-
come.
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